Invicro and icometrix Announce a Unique Partnership to Provide an Automated Workflow for Imaging Core Lab Services and Advanced Informatics to Pharmaceutical and Biotechnology Sponsors Worldwide

(Boston, MA and Leuven, Belgium) February 25, 2019 – Invicro LLC, a Konica Minolta company and icometrix jointly announced a partnership that will seamlessly offer the world’s most comprehensive breadth of imaging core lab services combined with the most robust FDA-cleared MRI informatics capabilities through automated workflows. Pharmaceutical sponsors will experience one point of contact for study site set-up and training which will harmonize with a single platform for data management, sharing and analytics.

(more…)

Invicro Appoints Dr. Joseph Krueger as Vice President, Research and Applications for Advanced Pathology Services

BOSTON, MA, February 14, 2019 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Dr. Joseph Krueger as Vice President, Research and Applications for Advanced Pathology Services.

(more…)

Konica Minolta Launches Dedicated Precision Medicine Business in Japan

Tokyo, Japan (September 26, 2018 – article source from Business Wire): Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) today announced the launch of Konica Minolta Precision Medicine Japan, Inc. (“KMPMJ”) which will start operations on October 1, 2018. KMPMJ is a 100%-owned subsidiary of Konica Minolta with responsibility for marketing high-end precision medicine tools and diagnostic services in Japan. Precision medicine is medical care that uses genetic and molecular profiling to optimize treatment for specific groups of patients.

(more…)

Invicro and Enigma Biomedical Group Sign a Collaboration Agreement

Toronto, Canada (August 20, 2018):  Enigma Biomedical Group (EBG) today announced a collaboration agreement with Invicro, a Konica Minolta Company and a leading provider of imaging services and software for research and drug development, to work together on multiple projects, initially focusing on the enhancement of Invicro’s AmyloidIQ and TauIQ platforms. EBG will be responsible for providing data from their affiliate companies; Cerveau Technologies, Inc. and Meilleur Technologies, Inc.; novel Tau tracer (MK-6240) and Amyloid tracer (NAV-4694); respectively.

(more…)

Dr. John E. Niederhuber Appointed Chairman of Konica Minolta’s Scientific Advisory Board

Aliso Viejo, CA (July 10, 2018):  Konica Minolta Precision Medicine Inc., a newly formed division of Konica Minolta focused on revolutionizing personalized patient care, announced today the appointment of Dr. John E. Niederhuber as the Chairman of their Scientific Advisory Board.

(more…)

Invicro Names Dr. Brian Avants as Senior Director of Machine Learning

BOSTON, MA, August 2, 2018 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the appointment of Brian Avants, Ph.D. as Senior Director of Machine Learning.

(more…)

Invicro Scientists Awarded Alavi-Mandell Publication Award and Named Finalist for the Ziskind-Somerfeld Research Award

BOSTON, MA, July 19, 2018 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, announces that a study conducted at Invicro London (formerly Imanova) has been awarded the Alavi-Mandell Publication Award by the Journal of Nuclear Medicine (JNM) for the publication entitled, “11C-PBR28 or 18F-PBR111 detect white matter inflammatory heterogeneity in multiple sclerosis”. Dr Gourab Datta, of Imperial College, London is lead author and award recipient.  Invicro’s Dr. Eugenii (Ilan) Rabiner, EVP Head of Translational Imaging and Dr. Roger Gunn, EVP of Quantitative Data Sciences are named co-authors.    

(more…)

Invicro Hires Peter Genakos as New Haven’s General Manager

BOSTON, MA, April 20, 2018 – Invicro, LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the appointment of Mr. Peter Genakos, J.D. as General Manager of the New Haven, CT office.

(more…)

Invicro Launches AmyloidIQ to Advance Clinical Imaging Trials in Alzheimer’s Disease

BOSTON, MA, March 19, 2018 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, recently announced the launch of AmyloidIQ, a new and advanced algorithm that quantifies Amyloid scans for use in subject stratification and clinical trials of Alzheimer’s disease therapies.

This novel algorithm calculates a single measure of the brain’s amyloid level denoted amyloid load, offering increased efficiencies within clinical imaging trials.  The new method encodes expert domain knowledge into an artificial intelligence algorithm that can accurately calculate the level of amyloid plaques in the brain. Test data from the Alzheimer’s Disease Neuroimaging Initiative database containing over 900 [18F] Florbetapir scans were analyzed with the new method and resulted in a 50% increase in power over other existing methods.   This technique opens the possibility of detecting smaller changes sooner, allowing clinical trials to run more efficiently and cost effectively by using reduced-size trials while achieving the same results.

Co-inventor and EVP of Quantitative Data Sciences for Invicro, Professor Roger Gunn, states, “By encoding expert domain knowledge into a computer algorithm for image analysis of amyloid scans we can increase power, reducing cost and timelines for clinical trials of novel AD therapeutics. This provides more powerful tools to Pharmaceutical Companies working in this important and challenging area.”

Professor Gunn collaborated with Dr. Alexander Whittington to develop and launch this innovative technique, which was presented and well received at the 12th Annual Human Amyloid Imaging Conference (HAI) in Miami, Florida. HAI 2018 provides an opportunity for academia and industry to share cutting edge advances in understanding amyloid pathology and its measurement in neurodegenerative disease.

For more information about AmyloidIQ or the use of amyloid Load analytics capabilities in clinical imaging trials, please contact AmyloidLoad@invicro.com and an Invicro specialist will be in touch.

About Invicro

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.  Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market.  For more information, visit www.invicro.com

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/

 

Media Contact:

Amanda Harrell

VP, Global Marketing

media@invicro.com

Invicro Hires Edward Hogan as Senior Vice President of Clinical Operations

Invicro Hires Edward Hogan as Senior Vice President of Clinical Operations

BOSTON, MA, February 27, 2018 – Invicro, LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Mr. Edward Hogan, M.S. as Senior Vice President of Clinical Operations.  Mr. Hogan brings extensive medical imaging and clinical research experience that will significantly advance Invicro’s clinical imaging core lab capabilities across all stages of the drug development pipeline (Phase I-IV).

“On behalf of the Invicro family, I welcome Ed to the team,” stated Dr. Jack Hoppin, Co-Founder and CEO of Invicro. “Ed’s appointment is a great addition to our clinical and senior leadership teams as he focuses on expanding our global clinical imaging capabilities into multiple therapeutic areas beyond neurology such as oncology, cardiovascular, and musculoskeletal to name a few. Through his leadership and his clinical operations expertise, our pharmaceutical and biotechnology sponsors will receive the most comprehensive imaging informatics service and support the industry has to offer.”

Mr. Hogan joins Invicro from PAREXEL, where he most recently initiated quality and process improvement efforts as the Vice President of the Quality First Program. Previously, he spent seven years as the Vice President of Imaging Operations, where he provided operational leadership, and launched core labs to support global growth in Europe, India, Japan and China.  During his time at PAREXEL he built and developed a cross-functional Medical Imaging team that grew from 20 to 450+ global employees to support over 1200 projects from Phase I-IV during his tenure.

“I am extremely excited to join the Invicro team,” Mr. Hogan stated. “I look forward to optimizing workflows that will leverage synergies between the core lab, the software team and the advanced analytics group.  Together, we will build upon our current best-in-class informatics offering that will provide research collaborators extensive analytics and secure data access.”

Prior to his sixteen-year career at PAREXEL, Mr. Hogan served as a Senior Medical Imaging Scientist at DuPont Merck where he led efforts to coordinate the imaging responsibilities of both internal and external core labs and earned the Executive Council Award for commitment to excellence. Mr. Hogan earned an MS in Electrical Engineering from Tufts and a BS in Electrical Engineering from the University of Lowell.

About Invicro

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.  Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market.  For more information, visit www.invicro.com

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/